Amicus Therapeutics, Inc.
FOLD
Pozycja w akcjach
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Cena akcji
$14.49
Ostatnia synchronizacja: 2026-04-27
Kapitalizacja rynkowa
$4.55B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
80.22%
Kraj
US
Handel Amicus Therapeutics, Inc. (FOLD)
Kategoria
Healthcare
Marża operacyjna dla Amicus Therapeutics, Inc. (FOLD)
Marża operacyjna na dzień October 2026 TTM: 8.00%
Według najnowszych raportów finansowych i ceny akcji Amicus Therapeutics, Inc., bieżąca marża operacyjna (TTM) wynosi 8.00%. Na koniec 2023 wynosiła -19.33%.
Historia marży operacyjnej dla Amicus Therapeutics, Inc. od 2003 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 8.00% | 69.85% |
| 2024 | 4.71% | -124.37% |
| 2023 | -19.33% | -68.87% |
| 2022 | -62.09% | -5.12% |
| 2021 | -65.44% | -29.99% |
| 2020 | -93.47% | -43.36% |
| 2019 | -165.03% | -54.20% |
| 2018 | -360.32% | -69.89% |
| 2017 | -1,196.82% | -67.38% |
| 2016 | -3,668.62% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -5,612.83% | -68.25% |
| 2013 | -17,680.72% | 6,049.82% |
| 2012 | -287.50% | 21.10% |
| 2011 | -237.41% | -96.08% |
| 2010 | -6,056.18% | 52,931.35% |
| 2009 | -11.42% | -96.11% |
| 2008 | -293.69% | -88.56% |
| 2007 | -2,567.54% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -95.18% |
US
|
|
| -149.01% | -118.63% |
US
|
|
| 25.57% | -96.80% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -96.40% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.